Lysinuric Protein Intolerance (LPI) Cell Models for Research

Lysinuric Protein Intolerance (LPI) is a rare autosomal recessive disorder caused by mutations in the SLC7A7 gene, which encodes the y+LAT1 amino acid transporter. The global prevalence is estimated at 1 in 50,000 to 1 in 100,000, with higher incidence in Finnish populations (1 in 60,000). The disease presents in infancy with vomiting, diarrhea, failure to thrive, and hyperammonemia. Long-term complications include pulmonary alveolar proteinosis, renal disease, and immune dysfunction. The 5-year survival is difficult to estimate due to rarity, but early diagnosis and dietary management improve outcomes. The disease burden is significant due to chronic complications and the need for lifelong management.

LPI serves as an excellent model for studying amino acid transport, urea cycle disorders, and the systemic effects of transporter dysfunction. The disease is monogenic, making it amenable to gene editing. Public datasets include ClinVar for mutations and NCBI Gene for SLC7A7. Open questions include the molecular mechanisms of pulmonary and renal involvement, and the role of y+LAT1 in immune function. Gene-edited cell models are crucial for mechanistic studies and drug development.

The primary defect is in the y+LAT1 transporter, which mediates the efflux of cationic amino acids (lysine, arginine, ornithine) from cells. This leads to:

• • Impaired intestinal absorption and renal reabsorption of these amino acids.
• • Disrupted urea cycle due to deficiency of ornithine and arginine, causing hyperammonemia.
• • Secondary dysfunction in nitric oxide synthesis due to arginine deficiency.
• • Altered immune responses due to impaired T-cell function.

Data from ClinVar and NCBI Gene.

The loss of y+LAT1 function affects multiple signaling pathways:

• • mTORC1 pathway: Amino acid sensing is impaired, leading to altered cell growth and metabolism.
• • Nitric oxide (NO) signaling: Reduced arginine availability decreases NO production, affecting vascular and immune functions.
• • Urea cycle enzymes: Ornithine deficiency impairs the urea cycle, leading to hyperammonemia.
• • Immune signaling: T-cell activation and proliferation are compromised due to impaired amino acid transport.

Organoids derived from patient intestinal or renal tissues can recapitulate disease phenotypes and are valuable for studying transporter function and drug responses.

• • Slc7a7 knockout mice: Generated via homologous recombination; exhibit growth retardation, hyperammonemia, and immune defects.
• • Patient-derived xenografts (PDX): Not commonly used due to the metabolic nature of the disease.
• • Induced models: CRISPR-mediated knockout in mice to study tissue-specific effects.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise SLC7A7 mutations. Examples include:

• • SLC7A7 knockout cell lines: Complete loss of function to model null mutations.
• • Knock-in cell lines with specific patient mutations: e.g., c.895-2A>G to model splicing defects.
• • Reporter cell lines: e.g., GFP-tagged SLC7A7 to study localization and trafficking.

These sequence-verified models are commercially available and accelerate research by providing consistent, reproducible systems for functional studies and drug screening.

Knockout and knock-in lines are used to validate the function of SLC7A7 and its variants. For example, a SLC7A7 knockout in HEK293 cells can be used to study amino acid transport kinetics and identify compensatory transporters. Knock-in lines with specific mutations allow genotype-phenotype correlations.

Isogenic pairs (wild-type vs. knockout) are used in high-throughput screens to identify compounds that rescue the transport defect or modulate downstream pathways. Resistance mechanisms to drugs that target amino acid metabolism can be studied by generating resistant cell lines.

CRISPR-based synthetic lethality screens can identify genes that are essential in SLC7A7-deficient cells, revealing potential therapeutic targets. Biomarkers for disease progression can be discovered by comparing transcriptomic and proteomic profiles of edited vs. wild-type cells.